[Therapy of invasive organ mycoses in patients with systemic hematologic diseases]

Area of Science:

• Mycology
• Hematology
• Infectious Diseases

Background:

• Invasive fungal infections (IFIs) are increasingly prevalent in immunocompromised patients, particularly those with acute leukemia or undergoing allogeneic stem cell transplantation.
• Aspergillus and Candida species are the most common causative agents of IFIs in these vulnerable populations.
• Despite advancements, evidence from randomized controlled trials for antifungal therapies in proven IFIs remains limited.

Purpose of the Study:

• To review current treatment strategies for documented invasive fungal infections in immunocompromised patients.
• To evaluate the role and limitations of existing and novel antifungal agents.
• To discuss emerging challenges such as antifungal resistance and treatment costs.

Main Methods:

• Literature review focusing on antifungal drug efficacy, safety, and resistance patterns.
• Analysis of treatment guidelines and clinical trial data for invasive fungal infections.
• Discussion of conventional and newer antifungal agents, including azoles and amphotericin B formulations.

Main Results:

• Conventional Amphotericin B is the gold standard but associated with significant nephrotoxicity and infusion-related adverse events.
• Azoles (fluconazole, itraconazole, voriconazole) are generally well-tolerated but fluconazole lacks activity against Aspergillus and faces emerging resistance in non-albicans Candida species.
• Lipid formulations of amphotericin B offer an alternative but are limited by high costs.

Conclusions:

• Optimal management of IFIs in high-risk patients requires careful consideration of drug efficacy, toxicity, resistance profiles, and cost-effectiveness.
• Further research, including randomized controlled trials, is needed to establish optimal treatment strategies for IFIs.
• Emerging antifungal agents and formulations require thorough evaluation to address current therapeutic challenges.